Valeant Pharmaceuticals International (VRX) 122.05 $VRX
Valeant Pharmaceuticals International Down 14.8% Since SmarTrend Downtrend Call (VRX)
Comtex SmarTrend(R) - Tue Apr 15, 9:58AM CDT
SmarTrend identified a Downtrend for Valeant Pharmaceuticals International (NYSE:VRX) on March 7th, 2014 at $138.23. In approximately 1 month, Valeant Pharmaceuticals International has returned 14.82% as of today's recent price of $117.75.
Is This the Time to Buy Pharma Stocks?
Brendan Mathews, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
In this edition of The Motley Fool's "Ask a Fool" series, Motley Fool One analyst Jason Moser and Motley Fool Stock Advisor analyst Brendan Mathews take a question from a reader who asks: "Many pharma companies went down 30 to 40%. Is it good...
30-Year Ultra Long Gilt Futures Updates, Partnerships, Notes Offer Pricings, and Drug Approvals - Analyst Notes on IntercontinentalExchange, Western Union, Essex Property , Valeant and Pharmacyclics
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding IntercontinentalExchange, Inc. (NYSE: ICE), The Western Union Company (NYSE: WU), Essex Property Trust Inc. (NYSE: ESS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Pharmacyclics Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1135-100free.
Facebook, Walgreen Climb Monday On International News
at Investor's Business Daily - Mon Apr 14, 4:32PM CDT
Overseas news helped boost two U.S. industry leaders Monday, with Walgreen (WAG) gaining 3% and Facebook (FB) up 2%. Facebook is reportedly within weeks of potential permission from Ireland's central bank that would authorize it to add financial...
Watch for Valeant Pharmaceuticals International to Potentially Rebound After Falling 1.49% Yesterday
Comtex SmarTrend(R) - Mon Apr 14, 3:49PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $115.77 to a high of $122.59. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $118.78 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Finishes Near 4000 Level In Another Sell-Off
at Investor's Business Daily - Fri Apr 11, 3:33PM CDT
The stock market suffered another sharp sell-off Friday, finishing the week with the Nasdaq just below the 4000 level for the first time since Feb. 3. The Nasdaq fell 1.3%; the S&P 500 was down 1% and the Dow Jones industrial average was off 0.9%....
Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
Shares of VRX Down 13.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 08, 9:30AM CDT
SmarTrend identified a Downtrend for Valeant Pharmaceuticals International (NYSE:VRX) on March 7th, 2014 at $138.23. In approximately 1 month, Valeant Pharmaceuticals International has returned 13.58% as of today's recent price of $119.46.
SmarTrend Watching for Potential Rebound in Shares of Valeant Pharmaceuticals International After 4.38% Loss
Comtex SmarTrend(R) - Mon Apr 07, 4:23PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $117.25 to a high of $125.14. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $121.91 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Is There Opportunity in the Eye-Care Sector?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 07, 8:30AM CDT
Imperfect vision is a common problem around the world. It's the basis for large businesses at Essilor , Hoya , and Luxottica , as well as contact-lens manufacturers like Johnson & Johnson , Novartis , Cooper , and Valeant . Not only...
Drug Recommendations, Legal Updates, Awards, Stock Price Movements, and Upcoming Results and Conference Call Schedules - Analyst Notes on MannKind, Mylan, WellPoint, Valeant, and Forest Laboratories
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corporation (NASDAQ: MNKD), Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
IBD 50 Stocks Fade With Market; Some Trip Sell Rules
at Investor's Business Daily - Fri Apr 04, 5:28PM CDT
A number of IBD 50 stocks are flashing warning signals amid the market's renewed sell-off. Facebook (FB) reversed lower this past week and fell 5% in heavy volume. The stock has fallen for four straight weeks, piercing its 10-week moving average and...
SmarTrend Watching for Potential Pullback in Shares of Valeant Pharmaceuticals International After 1.08% Gain
Comtex SmarTrend(R) - Tue Apr 01, 5:31PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $131.40 to a high of $136.43. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $132.33 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Drug, Airline Stocks Top Shortened Weekly Review
at Investor's Business Daily - Thu Mar 27, 4:51PM CDT
The list of stocks in Your Weekly Review has shrunk to fewer than 100 this week amid turmoil in the overall market. The reason for the shortened list is that many stocks have fallen more than 15% below their 52-week highs, violating one of the...
Actavis-Valeant Antibiotic Approved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 4:40PM CDT
Actavis and Valeant Pharma announced that the FDA has cleared metronidazole 1.3% vaginal gel.
Will Shire PLC Build Or Buy Its Future?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 26, 1:30PM CDT
The ideal in the biotech and pharma world may be for a company to develop a strong internal R&D engine that regularly churns out potential blockbuster compounds, but the reality is that most companies have to turn to partnerships and acquisitions...
Moody's Foresees Junky Valeant Pharmaceuticals Deals
at The Street - Wed Mar 26, 10:56AM CDT
Moody's isn't excited about the prospect of further consolidation in the generic drugs industry.
Actavis & Valeant Pharmaceuticals International partnership awarded US FDA's approval for Metronidazole 1.3% Vaginal Gel's NDA for the treatment of bacterial vaginosis
M2 - Wed Mar 26, 3:06AM CDT
Pharmaceutical company Actavis (NYSE:ACT) and Valeant Pharmaceuticals International (NYSE:VRX) on Tuesday jointly announced US Food and Drug Administration's (FDA) approval for the New Drug Application (NDA) for the antibiotic Metronidazole 1.3% Vaginal Gel for the treatment of bacterial vaginosis (BV).
Valeant Pharmaceuticals International Down 14.8% Since SmarTrend Downtrend Call (VRX)
Comtex SmarTrend(R) - Tue Apr 15, 9:58AM CDT
SmarTrend identified a Downtrend for Valeant Pharmaceuticals International (NYSE:VRX) on March 7th, 2014 at $138.23. In approximately 1 month, Valeant Pharmaceuticals International has returned 14.82% as of today's recent price of $117.75.
Is This the Time to Buy Pharma Stocks?
Brendan Mathews, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
In this edition of The Motley Fool's "Ask a Fool" series, Motley Fool One analyst Jason Moser and Motley Fool Stock Advisor analyst Brendan Mathews take a question from a reader who asks: "Many pharma companies went down 30 to 40%. Is it good...
30-Year Ultra Long Gilt Futures Updates, Partnerships, Notes Offer Pricings, and Drug Approvals - Analyst Notes on IntercontinentalExchange, Western Union, Essex Property , Valeant and Pharmacyclics
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding IntercontinentalExchange, Inc. (NYSE: ICE), The Western Union Company (NYSE: WU), Essex Property Trust Inc. (NYSE: ESS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Pharmacyclics Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1135-100free.
Facebook, Walgreen Climb Monday On International News
at Investor's Business Daily - Mon Apr 14, 4:32PM CDT
Overseas news helped boost two U.S. industry leaders Monday, with Walgreen (WAG) gaining 3% and Facebook (FB) up 2%. Facebook is reportedly within weeks of potential permission from Ireland's central bank that would authorize it to add financial...
Watch for Valeant Pharmaceuticals International to Potentially Rebound After Falling 1.49% Yesterday
Comtex SmarTrend(R) - Mon Apr 14, 3:49PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $115.77 to a high of $122.59. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $118.78 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Finishes Near 4000 Level In Another Sell-Off
at Investor's Business Daily - Fri Apr 11, 3:33PM CDT
The stock market suffered another sharp sell-off Friday, finishing the week with the Nasdaq just below the 4000 level for the first time since Feb. 3. The Nasdaq fell 1.3%; the S&P 500 was down 1% and the Dow Jones industrial average was off 0.9%....
Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
Shares of VRX Down 13.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 08, 9:30AM CDT
SmarTrend identified a Downtrend for Valeant Pharmaceuticals International (NYSE:VRX) on March 7th, 2014 at $138.23. In approximately 1 month, Valeant Pharmaceuticals International has returned 13.58% as of today's recent price of $119.46.
SmarTrend Watching for Potential Rebound in Shares of Valeant Pharmaceuticals International After 4.38% Loss
Comtex SmarTrend(R) - Mon Apr 07, 4:23PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $117.25 to a high of $125.14. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $121.91 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Is There Opportunity in the Eye-Care Sector?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 07, 8:30AM CDT
Imperfect vision is a common problem around the world. It's the basis for large businesses at Essilor , Hoya , and Luxottica , as well as contact-lens manufacturers like Johnson & Johnson , Novartis , Cooper , and Valeant . Not only...
Drug Recommendations, Legal Updates, Awards, Stock Price Movements, and Upcoming Results and Conference Call Schedules - Analyst Notes on MannKind, Mylan, WellPoint, Valeant, and Forest Laboratories
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corporation (NASDAQ: MNKD), Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
IBD 50 Stocks Fade With Market; Some Trip Sell Rules
at Investor's Business Daily - Fri Apr 04, 5:28PM CDT
A number of IBD 50 stocks are flashing warning signals amid the market's renewed sell-off. Facebook (FB) reversed lower this past week and fell 5% in heavy volume. The stock has fallen for four straight weeks, piercing its 10-week moving average and...
SmarTrend Watching for Potential Pullback in Shares of Valeant Pharmaceuticals International After 1.08% Gain
Comtex SmarTrend(R) - Tue Apr 01, 5:31PM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $131.40 to a high of $136.43. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $132.33 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Drug, Airline Stocks Top Shortened Weekly Review
at Investor's Business Daily - Thu Mar 27, 4:51PM CDT
The list of stocks in Your Weekly Review has shrunk to fewer than 100 this week amid turmoil in the overall market. The reason for the shortened list is that many stocks have fallen more than 15% below their 52-week highs, violating one of the...
Actavis-Valeant Antibiotic Approved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 4:40PM CDT
Actavis and Valeant Pharma announced that the FDA has cleared metronidazole 1.3% vaginal gel.
Will Shire PLC Build Or Buy Its Future?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 26, 1:30PM CDT
The ideal in the biotech and pharma world may be for a company to develop a strong internal R&D engine that regularly churns out potential blockbuster compounds, but the reality is that most companies have to turn to partnerships and acquisitions...
Moody's Foresees Junky Valeant Pharmaceuticals Deals
at The Street - Wed Mar 26, 10:56AM CDT
Moody's isn't excited about the prospect of further consolidation in the generic drugs industry.
Actavis & Valeant Pharmaceuticals International partnership awarded US FDA's approval for Metronidazole 1.3% Vaginal Gel's NDA for the treatment of bacterial vaginosis
M2 - Wed Mar 26, 3:06AM CDT
Pharmaceutical company Actavis (NYSE:ACT) and Valeant Pharmaceuticals International (NYSE:VRX) on Tuesday jointly announced US Food and Drug Administration's (FDA) approval for the New Drug Application (NDA) for the antibiotic Metronidazole 1.3% Vaginal Gel for the treatment of bacterial vaginosis (BV).
